Nusinersen (Spinraza®) is an antisense oligonucleotide that modifies SMN2 splicing when administered intrathecally; it was approved by the FDA in 2016 and by the European Medicines Agency (EMA) in 2017 for all subtypes of SMA. Here, SMN2 is linked to proximal spinal muscular atrophy.